Aqueous Extract of Cimicifuga dahurica Reprogramming Macrophage Polarization by Activating TLR4-NF-κB Signaling Pathway

References

• Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972. doi:10.1182/blood-2007-10-078022
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479–491.
   PubMed Web of Science ®Google Scholar
• Anderson KC. The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–452. doi:10.1200/JCO.2011.37.8919
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555. doi:10.1016/S1471-4906(02)02302-5
   PubMed Web of Science ®Google Scholar
• Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia. 2016;30(4):951–954. doi:10.1038/leu.2015.191
   PubMed Web of Science ®Google Scholar
• Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): implications in multiple myeloma. Leuk Res. 2015;39(9):971–975. doi:10.1016/j.leukres.2015.06.003
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J, Qian J, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013;27(3):702–710. doi:10.1038/leu.2012.272
   PubMed Web of Science ®Google Scholar
• Chen J, He D, Chen Q, et al. BAFF is involved in macrophage-induced bortezomib resistance in myeloma. Cell Death Dis. 2017;8(11):e3161. doi:10.1038/cddis.2017.533
   PubMed Web of Science ®Google Scholar
• Gutiérrez-González A, Martínez-Moreno M, Samaniego R, et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 2016;128(18):2241–2252. doi:10.1182/blood-2016-01-695395
   PubMed Web of Science ®Google Scholar
• Wang Q, Lu Y, Li R, et al. Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. Leukemia. 2018;32(1):176–183. doi:10.1038/leu.2017.193
   PubMed Web of Science ®Google Scholar
• Ou T, Dai X, Sun X. Discussion on theory and practice of treating multiple myeloma based on shengma biejia decoction and beating chemotherapy. Chin J Tradit Chin Med. 2020;27:123–125. doi:10.19879/j.cnki.1005-5304.201901353
   Google Scholar
• Dai H, Ma B, Dai X, et al. Shengma biejia decoction inhibits cell growth in multiple myeloma by Inducing autophagy-mediated apoptosis through the ERK/mTOR pathway. Front Pharmacol. 2021;12:585286. doi:10.3389/fphar.2021.585286
   PubMed Web of Science ®Google Scholar
• Guo Y, Yin T, Wang X, et al. Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: a review. J Ethnopharmacol. 2017;209:264–282. doi:10.1016/j.jep.2017.07.040
   PubMed Web of Science ®Google Scholar
• Li JX, Yu ZY. Cimicifugae rhizoma: from origins, bioactive constituents to clinical outcomes. Curr Med Chem. 2006;13(24):2927–2951. doi:10.2174/092986706778521869
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi:10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114(17):3625–3628. doi:10.1182/blood-2009-05-220285
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Remark R, Damotte D, Sautès-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol. 2014;27:8–15. doi:10.1016/j.coi.2014.01.001
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737. doi:10.1038/nri3073
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008
   PubMed Web of Science ®Google Scholar
• Chen X, Chen J, Zhang W, et al. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget. 2017;8(68):112685–112696. doi:10.18632/oncotarget.22340
   PubMedGoogle Scholar
• Wang H, Hu WM, Xia ZJ, et al. High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J Cancer. 2019;10(14):3239–3245. doi:10.7150/jca.30102
   PubMed Web of Science ®Google Scholar
• Qian S, Zhang H, Dai H, et al. Is sCD163 a clinical significant prognostic value in cancers? A systematic review and meta-analysis. Front Oncol. 2020;10:585297. doi:10.3389/fonc.2020.585297
   PubMed Web of Science ®Google Scholar
• Saeedifar AM, Mosayebi G, Ghazavi A, Bushehri RH, Ganji A. Macrophage polarization by phytotherapy in the tumor microenvironment. Phytother Res. 2021;35(7):3632–3648. doi:10.1002/ptr.7058
   PubMed Web of Science ®Google Scholar
• Han X, Wei Q, Lv Y, et al. Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. Mol Ther. 2021;30(1):327–340. doi:10.1016/j.ymthe.2021.08.028
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fu X, Xu L, et al. Nanosized alumina particle and proteasome inhibitor bortezomib prevented inflammation and osteolysis induced by titanium particle via autophagy and NF-κB signaling. Sci Rep. 2020;10(1):5562. doi:10.1038/s41598-020-62254-x
   PubMed Web of Science ®Google Scholar
• Jiang L, Song J, Hu X, et al. The proteasome inhibitor bortezomib inhibits inflammatory response of periodontal ligament cells and ameliorates experimental periodontitis in rats. J Periodontol. 2017;88(5):473–483. doi:10.1902/jop.2016.160396
   PubMed Web of Science ®Google Scholar
• Meiners S, Ludwig A, Stangl V, Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev. 2008;28(2):309–327. doi:10.1002/med.20111
   PubMed Web of Science ®Google Scholar
• Hu LH, Fan YJ, Li Q, et al. Bortezomib protects against dextran sulfate sodium‑induced ulcerative colitis in mice. Mol Med Rep. 2017;15(6):4093–4099. doi:10.3892/mmr.2017.6524
   PubMed Web of Science ®Google Scholar
• Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer. 2010;46(2):420–429. doi:10.1016/j.ejca.2009.10.019
   PubMed Web of Science ®Google Scholar
• Kim J, Denu RA, Dollar BA, et al. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012;158(3):336–346. doi:10.1111/j.1365-2141.2012.09154.x
   PubMed Web of Science ®Google Scholar
• Li X, Liu R, Su X, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer. 2019;18(1):177. doi:10.1186/s12943-019-1102-3
   PubMed Web of Science ®Google Scholar
• Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577. doi:10.1186/s12885-015-1546-9
   PubMed Web of Science ®Google Scholar
• Bryant CE, Symmons M, Gay NJ. Toll-like receptor signalling through macromolecular protein complexes. Mol Immunol. 2015;63(2):162–165. doi:10.1016/j.molimm.2014.06.033
   PubMed Web of Science ®Google Scholar
• Almog T, Kandel-Kfir M, Shaish A, et al. Knockdown of interleukin-1α does not attenuate LPS-induced production of interleukin-1β in mouse macrophages. Cytokine. 2015;73(1):138–143. doi:10.1016/j.cyto.2015.01.029
   PubMed Web of Science ®Google Scholar
• Liu H, Chen K, Feng W, Wu X, Li H. TLR4-MyD88/Mal-NF-kB axis is involved in infection of HSV-2 in human cervical epithelial cells. PLoS One. 2013;8(11):e80327. doi:10.1371/journal.pone.0080327
   PubMed Web of Science ®Google Scholar
• Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. 2005;175(1):342–349. doi: 10.4049/jimmunol.175.1.342
   PubMed Web of Science ®Google Scholar
• Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014;5:614. doi:10.3389/fimmu.2014.00614
   PubMed Web of Science ®Google Scholar
• Wanderley CW, Colón DF, Luiz JPM, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 2018;78(20):5891–5900. doi:10.1158/0008-5472.CAN-17-3480
   PubMed Web of Science ®Google Scholar
• Wu L, Chen ZL, Su Y, Wang QH, Kuang HX. Cycloartenol triterpenoid saponins from cimicifuga simplex (Ranunculaceae) and their biological effects. Chin J Nat Med. 2015;13(2):81–89. doi:10.1016/S1875-5364(15)60011-5
   PubMed Web of Science ®Google Scholar